Since Ramucirumab is a VEGFR2 antagonist that blocks the binding of VEGF-A, VEGF-C, and VEGF-D, we analyzed the mRNA expression and copy number alterations of these genes in gastric adenocarcinomas. Here, KDR is linked to gastric adenocarcinoma.